hit counter

Posttraumatic Growth in Farsi Refugees: 61% Explained by 4 Factors

Photoreal illustration of refugees in community setting with imagery of resilience and growth, conveying integrated trauma adaptation.

A 2026 survey of 230 Farsi-speaking refugees in German camps found a hard double signal: 69.1% screened above the RHS-15 threshold for depression, anxiety, and PTSD symptoms, while 4 protective factors explained 61% of posttraumatic-growth variance.1 Research Highlights High distress and growth coexisted: 159 of 230 participants (69.1%) scored ≥12 on the RHS-15 symptom scale, …

Read more

Cannabis After Pregnancy Did Not Increase Hypertension Risk in nuMoM2b

Photoreal illustration of a postpartum woman with stethoscope and cannabis imagery, conveying cardiovascular implications of postpartum cannabis use.

A 2026 nuMoM2b Heart Health Study analysis tested whether urine-confirmed cannabis exposure 2–7 years after a first pregnancy predicted incident stage II hypertension; it did not: adjusted odds ratio (AOR) 1.05, 95% CI 0.63–1.76, with 216 of 4,079 participants developing hypertension.1 Research Highlights The headline result was null: cannabis exposure at the 2–7 year postpartum …

Read more

Chronic Pain Plus Depression Alters Brain Structure

Photoreal illustration of brain regions affected by overlapping pain and depression networks, conveying comorbid neural signature.

A 2026 UK Biobank MRI preprint involving 71,214 adults found that chronic pain plus current depression had a structural brain profile that was more than chronic pain plus depression pasted together. The 1,377-person comorbid group showed widespread lower cortical volume, lower bilateral thalamic and hippocampal volume, lower left accumbens volume, and broad white-matter microstructure differences …

Read more

Methylphenidate Reduced Dishonesty and Cheating in 151 Adults; Atomoxetine Had No Effect

Editorial card showing methylphenidate molecular structure beside a die-rolling task, illustrating a counterintuitive randomized-trial result.

A 2026 double-blind randomized controlled trial by Kappes et al. in Psychopharmacology found something the smart-drug users likely wouldn’t have predicted: a single 30 mg dose of methylphenidate reduced dishonest misreporting on a die-rolling task from ~22% of trials in the placebo arm to ~6% (in the methylphenidate arm).1 Atomoxetine, a noradrenergic comparator, had no …

Read more

Transcranial Temporal Interference Stimulation (tTIS) May Improve Parkinson’s Motor Symptoms

Photoreal illustration of two interfering electric fields converging at deep brain regions, conveying non-invasive deep stimulation in Parkinson's.

Deep brain stimulation works for Parkinson’s, but it requires implanted electrodes. A 2026 randomized crossover trial by Stalter and colleagues tested whether transcranial temporal interference stimulation — a non-invasive technique designed to reach deep targets without exciting overlying cortex — can move the needle on motor symptoms when aimed at the putamen.1 Research Highlights Transcranial …

Read more

Antidepressant Use in Pakistan (2026): SSRI Prescribing Patterns and Patient-Reported Side Effects

Photoreal illustration of a pharmacist counseling patient on antidepressant medication, conveying global pharmacovigilance.

Most antidepressant pharmacovigilance data come from high-income countries, leaving prescribing patterns and adverse-effect profiles in low- and middle-income countries underdocumented. A 2026 cross-sectional study by Riaz and colleagues describes antidepressant use in Pakistan, with patient-reported adverse effects mapped against prescription patterns.1 Research Highlights Antidepressant use in low- and middle-income countries (LMICs) has grown substantially but …

Read more

Parkinson’s Disease Prevention: Prodromal Symptoms, RBD, Early Intervention Trials

Photoreal illustration of a brain with prodromal pathology and a clock indicating early-window intervention opportunity for Parkinson's prevention.

Parkinson’s disease has a years-to-decades prodromal stage where motor symptoms haven’t yet emerged but pathology is accumulating. A 2026 review by Schaeffer et al. synthesizes the case for (and limits of) intervening during this window — with implications for high-risk individuals weighing whether to enter preventive trials.1 Research Highlights Prodromal Parkinson’s disease is the period …

Read more